Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival

Leibovici, Dan; Grossman, H. Barton; Dinney, Colin P.; Millikan, R. E.; Lerner, Seth P.; Wang, Yunfei; Gu, Jian; Dong, Qiong; Wu, Xifeng

doi:10.1200/jco.2005.01.598

Cited by 147 publications

(112 citation statements)

References 28 publications

Supporting

Mentioning

106

Contrasting

Unclassified

Order By: Relevance

“…94 Recent studies have demonstrated that in bladder tumor cells, which PPARγ expression was weak or absent, standard therapy with Bacillus Calmette-Guerin therapy (BCG), induced cytoplasmic expression of PPARγ. 95 Additionally, it is noteworthy that the inhibition of cell viability by 15-d-PGJ 2 was only detected in the presence of BCG, and the effect of 15-d-PGJ 2 was PPARγ-dependent, since BADGE, a specific PPARγ antagonist, reversed the BCG-mediated cell cytotoxicity.…”

Section: Role In Cancer Biologymentioning

confidence: 99%

“…In bladder cancer, polymorphism in genes that regulate inflammatory process such as IL-6 and PPARγ are associated with recurrence risk, progression and survival. 94 Patients with PPARγ variant alleles (Single Nucleotide Polymorphism-Pro12Ala) show decreased PPARγ receptor activity and are associated with an increased risk of bladder cancer recurrence and progression. 94 The Our previous work had shown that modulation of glycogen synthase kinase-3 beta (GSK-3β) and cyclin D1 might be a predictor of response to EGFR inhibitors in bladder cancer.…”

Section: Pparγ and Pparγ-agonists In Bladder Cancermentioning

confidence: 99%

“…94 Patients with PPARγ variant alleles (Single Nucleotide Polymorphism-Pro12Ala) show decreased PPARγ receptor activity and are associated with an increased risk of bladder cancer recurrence and progression. 94 The Our previous work had shown that modulation of glycogen synthase kinase-3 beta (GSK-3β) and cyclin D1 might be a predictor of response to EGFR inhibitors in bladder cancer. 112 Taken together, combined targeting of both EGFR and PPARγ axes can reveal promising molecules to target in bladder cancer.…”

Section: Pparγ and Pparγ-agonists In Bladder Cancermentioning

confidence: 99%

See 2 more Smart Citations

Peroxisome proliferator-activated receptor γ in bladder cancer: A promising therapeutic target

Mansure¹,

Nassim²,

Kassouf³

2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

Section: Role In Cancer Biologymentioning

confidence: 99%

Section: Pparγ and Pparγ-agonists In Bladder Cancermentioning

confidence: 99%

Section: Pparγ and Pparγ-agonists In Bladder Cancermentioning

confidence: 99%

See 1 more Smart Citation

Peroxisome proliferator-activated receptor γ in bladder cancer: A promising therapeutic target

Mansure¹,

Nassim²,

Kassouf³

2009

Cancer Biology & Therapy

View full text Add to dashboard Cite

“…The TNF-α 308G/A polymorphism is a G/A polymorphism at nucleotide (nt) -308, and is associated with the development of several urogenital cancers, including prostate cancer (Zabaleta et al, 2008;Moore et al, 2009;Jones et al, 2013), cervical cancer (Singh, 2009;Zuo et al, 2011), bladder cancer (Jeong et al, 2004;Kim et al, 2005;Leibovici et al, 2005), and renal cell carcinoma (Jang et al, 2001). For example, Jeong et al (2004) studied 113 patients with bladder cancer and 109 healthy subjects and found that the genotype of the 308 nucleotide in the TNF-α promoter had a statistically significant effect on TNF-α production and was related to the bladder tumor grade.…”

Section: Discussionmentioning

confidence: 99%

“…There are 13 studies (Oh et al, 2000;McCarron et al, 2002;Wu, 2004;Jinchao, 2007;Danforth et al, 2008;Sáenz-López et al, 2008;Zabaleta et al, 2008;Kesarwani, 2009;Moore et al, 2009;Wang et al, 2009a;Zhang et al, 2010;Berhane et al, 2012;Jones et al, 2013) focusing on prostate cancer, 19 studies (Jang et al, 2001;Calhoun et al, 2002;Gostout et al, 2003;Stanczuk et al, 2003;Deshpande et al, 2005;Duarte et al, 2005;Govan, 2006;Kohaar et al, 2007;Singh, 2009;Wang et al, 2009b;Ivansson, 2010;Zu, 2010;Wang et al, 2011;Zuo et al, 2011;Badano et al, 2012;Barbisan et al, 2012;Hang and Xu, 2012;Wang et al, 2012;Sousa et al, 2014) on cervical cancer, 6 studies (Tsai et al, 2001;Jeong et al, 2004;Kim et al, 2005;Leibovici et al, 2005;Nonomura et al, 2006;Ahirwar et al, 2008) on bladder cancer, 1 study (Jang et al, 2001) on renal cell cancer, and 1 study (Wu, 2013) on urothelial carcinoma. Five articles (Stanczuk et al, 2003;…”

Section: Study Characteristicsmentioning

confidence: 99%

Association of tumor necrosis factor-α 308G/A polymorphism with urogenital cancer risk: a systematic review and meta-analysis

et al. 2015

View full text Add to dashboard Cite

ABSTRACT. We integrated all the eligible studies and investigated whether the TNF-α 308G/A polymorphism correlates with urogenital cancer risk. Tumor necrosis factor-α (TNF-α) is a risk factor for some urogenital cancers; however, in prostate and bladder cancers the results are controversial. PubMed, EMBASE, Web of Science, the Cochrane Library, the Chinese Biomedical Literature Database, and the Wanfang Database were searched for all case-control studies on the relationship between the TNF-α 308G/A polymorphism and susceptibility to urogenital cancer between January 1994 and January 2015. The pooled odds ratio with 95% confidence interval was calculated to assess the associations. A total of 16103 Association between TNF-α 308G/A and urogenital cancer risk ©FUNPEC-RP www.funpecrp.com.br Genetics and Molecular Research 14 (4): 16102-16112 (2015) 504 articles were found, 39 of which involved 11,613 cases and 12,542 controls that fulfilled the inclusion criteria. Overall, the TNF-α 308G/A polymorphism was significantly associated with the risk of urogenital cancer. In the subgroup analysis for different cancer types, significant associations were found in cervical cancer and urothelial carcinoma, while our metaanalysis indicated that there were no significant associations between the TNF-α 308G/A polymorphism and prostate, bladder, or renal cancers. When stratified by ethnicity, significant associations were observed in Caucasian populations, whereas no significant associations were found in African-Americans, Asians, or mixed populations. Furthermore, carriers of the -308A allele among the hospital-based case-control group were at a high risk of urogenital cancer. Our meta-analysis showed that the TNF-α 308G/A polymorphism was significantly associated with urogenital cancer risk, particularly in the Caucasian and hospital-based populations.

show abstract

Interleukin‐6 predicts recurrence and survival among head and neck cancer patients

Duffy

Taylor

Terrell

et al. 2008

Cancer

286

271

View full text Add to dashboard Cite

BACKGROUND. Increased pretreatment serum interleukin (IL)‐6 levels among patients with head and neck squamous cell carcinoma (HNSCC) have been shown to correlate with poor prognosis, but sample sizes in prior studies have been small and thus unable to control for other known prognostic variables. METHODS. A longitudinal, prospective cohort study determined the correlation between pretreatment serum IL‐6 levels, and tumor recurrence and all‐cause survival in a large population (N = 444) of previously untreated HNSCC patients. Control variables included age, sex, smoking, cancer site and stage, and comorbidities. Kaplan‐Meier plots and univariate and multivariate Cox proportional hazards models were used to study the association between IL‐6 levels, control variables, and time to recurrence and survival. RESULTS. The median serum IL‐6 level was 13 pg/mL (range, 0‐453). The 2‐year recurrence rate was 35.2% (standard error, 2.67%). The 2‐year death rate was 26.5% (standard error, 2.26%). Multivariate analyses showed that serum IL‐6 levels independently predicted recurrence at significant levels [hazard ratio (HR) = 1.32; 95% confidence interval (CI), 1.11 to 1.58; P = .002] as did cancer site (oral/sinus). Serum IL‐6 level was also a significant independent predictor of poor survival (HR = 1.22; 95% CI, 1.02 to 1.46; P = .03), as were older age, smoking, cancer site (oral/sinus), higher cancer stage, and comorbidities. CONCLUSIONS. Pretreatment serum IL‐6 could be a valuable biomarker for predicting recurrence and overall survival among HNSCC patients. Using IL‐6 as a biomarker for recurrence and survival may allow for earlier identification and treatment of disease relapse. Cancer 2008. © 2008 American Cancer Society.

show abstract

Polymorphisms in Inflammation Genes and Bladder Cancer: From Initiation to Recurrence, Progression, and Survival

Abstract: Inflammation gene polymorphisms are associated with modified BC risk, treatment response, and survival.

Cited by 147 publications

References 28 publications

Peroxisome proliferator-activated receptor γ in bladder cancer: A promising therapeutic target

Peroxisome proliferator-activated receptor γ in bladder cancer: A promising therapeutic target

Association of tumor necrosis factor-α 308G/A polymorphism with urogenital cancer risk: a systematic review and meta-analysis

Interleukin‐6 predicts recurrence and survival among head and neck cancer patients

Contact Info

Product

Resources

About